{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:24:03Z","timestamp":1784816643089,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19\\u20131-0284"],"award-info":[{"award-number":["W81XWH-19\\u20131-0284"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21\\u20131-0738"],"award-info":[{"award-number":["W81XWH-21\\u20131-0738"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01CA261669"],"award-info":[{"award-number":["P01CA261669"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA260857"],"award-info":[{"award-number":["R01CA260857"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03CA256764"],"award-info":[{"award-number":["R03CA256764"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA260872"],"award-info":[{"award-number":["R01CA260872"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA247441"],"award-info":[{"award-number":["R01CA247441"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.radonc.2025.110889","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:56:33Z","timestamp":1744163793000},"page":"110889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment"],"prefix":"10.1016","volume":"207","author":[{"given":"Eleni","family":"Gkika","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Firat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Adebahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Graf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilinca","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Eichhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Radicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon K.B.","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Nestle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils H.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Niedermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca-L.","family":"Grosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan G.","family":"Duda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.110889_b0005","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study","volume":"37","author":"Gomez","year":"2019","journal-title":"J clin Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0015","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0020","first-page":"1476","article-title":"Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA","volume":"7","author":"Siva","year":"2021","journal-title":"Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2025.110889_b0035","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0040","first-page":"9023","article-title":"Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer","volume":"36","author":"Theelen","year":"2018","journal-title":"The PEMBRO-RT study"},{"key":"10.1016\/j.radonc.2025.110889_b0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","article-title":"Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"9","author":"Theelen","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.radonc.2025.110889_b0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41698-023-00358-z","article-title":"Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer","volume":"7","author":"Gkika","year":"2023","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0055","doi-asserted-by":"crossref","unstructured":"Guckenberger, M. et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 190, 26-33 (2014). https:\/\/doi.org\/10.1007\/s00066-013-0450-y.","DOI":"10.1007\/s00066-013-0450-y"},{"key":"10.1016\/j.radonc.2025.110889_b0060","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0065","article-title":"LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective","volume":"88","author":"Adebahr","year":"2015","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2025.110889_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246193","article-title":"Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2025.110889_b0075","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"},{"key":"10.1016\/j.radonc.2025.110889_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100808","article-title":"The paradox of radiation and T cells in tumors","volume":"31","author":"Gough","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.radonc.2025.110889_b0085","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/hed.23535","article-title":"Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer","volume":"36","author":"Campian","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2025.110889_b0090","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2025.110889_b0095","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3389\/fimmu.2018.00547","article-title":"Spontaneous T Cell Proliferation: A Physiologic Process to Create and Maintain Homeostatic Balance and Diversity of the Immune System","volume":"9","author":"Min","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2025.110889_b0100","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2020.10.028","article-title":"Dynamic changes in circulating PD-1(+)CD8(+) T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer","volume":"143","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2025.110889_b0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2025.110889_b0110","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1172\/JCI127967","article-title":"Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes","volume":"129","author":"Gros","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.radonc.2025.110889_b0115","article-title":"PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?","volume":"7","author":"Simon","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2025.110889_b0120","article-title":"The role of cytokines in lymphocyte homeostasis","volume":"40\u201345","author":"Khaled","year":"2002","journal-title":"Biotechniques Suppl"},{"key":"10.1016\/j.radonc.2025.110889_b0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1286-4579(01)01509-X","article-title":"Regulation of na\u00efve and memory T-cell homeostasis","volume":"4","author":"Surh","year":"2002","journal-title":"Microbes Infect"},{"key":"10.1016\/j.radonc.2025.110889_b0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13046-023-02621-4","article-title":"Beyond lymphopenia, unraveling radiation-induced leucocyte subpopulation kinetics and mechanisms through modeling approaches","volume":"42","author":"Pham","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.radonc.2025.110889_b0135","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.radonc.2025.110889_b0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2025.110889_b0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.21037\/tlcr.2018.08.16","article-title":"Combining stereotactic body radiation therapy with immunotherapy: current data and future directions","volume":"8","author":"Lin","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.radonc.2025.110889_b0150","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00262-020-02587-8","article-title":"Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature","volume":"69","author":"Watanabe","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.radonc.2025.110889_b0155","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2025.110889_b0160","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0165","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2019.05.064","article-title":"Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy","volume":"105","author":"Ladbury","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2025.110889_b0170","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ab6c41","article-title":"4D blood flow model for dose calculation to circulating blood and lymphocytes","volume":"65","author":"Hammi","year":"2020","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.radonc.2025.110889_b0175","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.radonc.2022.10.019","article-title":"Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy","volume":"177","author":"Venkatesulu","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0180","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.radonc.2025.110889_b0185","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.radonc.2025.110889_b0190","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1186\/s12885-018-5086-y","article-title":"Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis","volume":"18","author":"Ai","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2025.110889_b0195","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20232101","article-title":"Radiotherapy and immunology","volume":"221","author":"Wang","year":"2024","journal-title":"J Exp Med"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025001847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T16:19:33Z","timestamp":1748017173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025001847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":39,"alternative-id":["S0167814025001847"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110889","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.110889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110889"}}